DK175779B1 - Komprimerede pulverlægemidler - Google Patents

Komprimerede pulverlægemidler Download PDF

Info

Publication number: DK175779B1
Authority: DK; Denmark
Prior art keywords: drug; patient; preparing; patient according; transmucosal delivery
Prior art date: 1985-05-01

Application number

DK199200193A

Other languages

Danish (da)

English (en)

Other versions

DK19392A (da

DK19392D0 (da

Inventor

Brian Hague

Theodore H Stanley

Original Assignee

Anesta Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-05-01

Filing date

1992-02-14

Publication date

2005-02-14

1989-08-24 Priority claimed from CA000609378A external-priority patent/CA1339190C/fr

1992-02-14 Application filed by Anesta Corp filed Critical Anesta Corp

1992-02-14 Publication of DK19392A publication Critical patent/DK19392A/da

1992-02-14 Publication of DK19392D0 publication Critical patent/DK19392D0/da

2005-02-14 Application granted granted Critical

2005-02-14 Publication of DK175779B1 publication Critical patent/DK175779B1/da

Links

239000011159 matrix material Substances 0.000 title claims abstract description 65
210000004400 mucous membrane Anatomy 0.000 title claims abstract description 26
239000003814 drug Substances 0.000 title claims description 356
229940079593 drug Drugs 0.000 title claims description 342
230000001624 sedative effect Effects 0.000 title abstract description 7
239000000932 sedative agent Substances 0.000 title abstract description 6
230000003444 anaesthetic effect Effects 0.000 title abstract 2
230000000202 analgesic effect Effects 0.000 title abstract 2
235000011475 lollipops Nutrition 0.000 claims abstract description 68
239000003795 chemical substances by application Substances 0.000 claims abstract description 41
238000003780 insertion Methods 0.000 claims abstract 2
230000037431 insertion Effects 0.000 claims abstract 2
238000000034 method Methods 0.000 claims description 91
210000000214 mouth Anatomy 0.000 claims description 40
239000000203 mixture Substances 0.000 claims description 38
230000000694 effects Effects 0.000 claims description 34
239000005913 Maltodextrin Substances 0.000 claims description 24
229920002774 Maltodextrin Polymers 0.000 claims description 24
229940035034 maltodextrin Drugs 0.000 claims description 24
238000002360 preparation method Methods 0.000 claims description 23
239000000872 buffer Substances 0.000 claims description 20
NZXKDOXHBHYTKP-UHFFFAOYSA-N Metohexital Chemical compound CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O NZXKDOXHBHYTKP-UHFFFAOYSA-N 0.000 claims description 17
229960002683 methohexital Drugs 0.000 claims description 17
238000010521 absorption reaction Methods 0.000 claims description 16
239000000796 flavoring agent Substances 0.000 claims description 15
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 14
210000003169 central nervous system Anatomy 0.000 claims description 13
238000004090 dissolution Methods 0.000 claims description 13
239000000463 material Substances 0.000 claims description 13
230000003389 potentiating effect Effects 0.000 claims description 13
239000007787 solid Substances 0.000 claims description 13
150000001720 carbohydrates Chemical class 0.000 claims description 12
235000014633 carbohydrates Nutrition 0.000 claims description 12
230000006835 compression Effects 0.000 claims description 11
238000007906 compression Methods 0.000 claims description 11
238000002844 melting Methods 0.000 claims description 11
230000008018 melting Effects 0.000 claims description 11
238000002156 mixing Methods 0.000 claims description 11
210000003800 pharynx Anatomy 0.000 claims description 10
210000003238 esophagus Anatomy 0.000 claims description 9
229960000201 isosorbide dinitrate Drugs 0.000 claims description 9
MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 claims description 9
235000003599 food sweetener Nutrition 0.000 claims description 8
239000003765 sweetening agent Substances 0.000 claims description 8
210000000748 cardiovascular system Anatomy 0.000 claims description 7
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 6
239000000006 Nitroglycerin Substances 0.000 claims description 6
NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 claims description 6
229960001690 etomidate Drugs 0.000 claims description 6
229960003711 glyceryl trinitrate Drugs 0.000 claims description 6
DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims description 5
235000019568 aromas Nutrition 0.000 claims description 5
229960004391 lorazepam Drugs 0.000 claims description 5
239000000314 lubricant Substances 0.000 claims description 5
ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 claims description 5
229960004535 oxazepam Drugs 0.000 claims description 5
230000002792 vascular Effects 0.000 claims description 5
229940069078 citric acid / sodium citrate Drugs 0.000 claims description 4
239000003623 enhancer Substances 0.000 claims description 4
235000013355 food flavoring agent Nutrition 0.000 claims description 4
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 4
229960001597 nifedipine Drugs 0.000 claims description 4
XLOMZPUITCYLMJ-UHFFFAOYSA-N thiamylal Chemical compound CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O XLOMZPUITCYLMJ-UHFFFAOYSA-N 0.000 claims description 4
229960001166 thiamylal Drugs 0.000 claims description 4
235000019264 food flavour enhancer Nutrition 0.000 claims description 3
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims description 2
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 2
229960000830 captopril Drugs 0.000 claims description 2
229960002896 clonidine Drugs 0.000 claims description 2
235000009508 confectionery Nutrition 0.000 description 72
239000004615 ingredient Substances 0.000 description 60
244000290333 Vanilla fragrans Species 0.000 description 39
235000009499 Vanilla fragrans Nutrition 0.000 description 39
235000012036 Vanilla tahitensis Nutrition 0.000 description 39
239000003094 microcapsule Substances 0.000 description 37
239000000047 product Substances 0.000 description 37
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 27
239000000843 powder Substances 0.000 description 22
239000006071 cream Substances 0.000 description 20
108091028664 Ribonucleotide Proteins 0.000 description 19
239000002552 dosage form Substances 0.000 description 19
235000010357 aspartame Nutrition 0.000 description 18
108010011485 Aspartame Proteins 0.000 description 17
239000000605 aspartame Substances 0.000 description 17
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 17
229960003438 aspartame Drugs 0.000 description 17
244000007021 Prunus avium Species 0.000 description 16
235000010401 Prunus avium Nutrition 0.000 description 16
235000014441 Prunus serotina Nutrition 0.000 description 16
238000002347 injection Methods 0.000 description 15
239000007924 injection Substances 0.000 description 15
206010039897 Sedation Diseases 0.000 description 11
235000019634 flavors Nutrition 0.000 description 11
230000036280 sedation Effects 0.000 description 11
235000006679 Mentha X verticillata Nutrition 0.000 description 10
235000002899 Mentha suaveolens Nutrition 0.000 description 10
235000001636 Mentha x rotundifolia Nutrition 0.000 description 10
230000015556 catabolic process Effects 0.000 description 10
239000000470 constituent Substances 0.000 description 10
238000006731 degradation reaction Methods 0.000 description 10
244000246386 Mentha pulegium Species 0.000 description 9
235000016257 Mentha pulegium Nutrition 0.000 description 9
235000004357 Mentha x piperita Nutrition 0.000 description 9
235000001050 hortel pimenta Nutrition 0.000 description 9
210000004185 liver Anatomy 0.000 description 9
235000019640 taste Nutrition 0.000 description 8
239000000243 solution Substances 0.000 description 7
238000001356 surgical procedure Methods 0.000 description 7
229940124597 therapeutic agent Drugs 0.000 description 7
238000009827 uniform distribution Methods 0.000 description 7
206010002091 Anaesthesia Diseases 0.000 description 6
230000037005 anaesthesia Effects 0.000 description 6
239000002249 anxiolytic agent Substances 0.000 description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
239000007788 liquid Substances 0.000 description 6
229940126601 medicinal product Drugs 0.000 description 6
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 5
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 5
208000002193 Pain Diseases 0.000 description 5
239000013543 active substance Substances 0.000 description 5
230000000949 anxiolytic effect Effects 0.000 description 5
230000008901 benefit Effects 0.000 description 5
229960004943 ergotamine Drugs 0.000 description 5
OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 5
XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 5
238000010348 incorporation Methods 0.000 description 5
229960004502 levodopa Drugs 0.000 description 5
150000002632 lipids Chemical class 0.000 description 5
239000007937 lozenge Substances 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
230000036407 pain Effects 0.000 description 5
239000003826 tablet Substances 0.000 description 5
JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 5
229960003386 triazolam Drugs 0.000 description 5
208000000044 Amnesia Diseases 0.000 description 4
208000031091 Amnestic disease Diseases 0.000 description 4
230000009471 action Effects 0.000 description 4
230000006986 amnesia Effects 0.000 description 4
230000003466 anti-cipated effect Effects 0.000 description 4
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 4
239000008116 calcium stearate Substances 0.000 description 4
235000013539 calcium stearate Nutrition 0.000 description 4
238000009826 distribution Methods 0.000 description 4
210000004379 membrane Anatomy 0.000 description 4
239000012528 membrane Substances 0.000 description 4
230000035882 stress Effects 0.000 description 4
230000009747 swallowing Effects 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
208000019901 Anxiety disease Diseases 0.000 description 3
108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 3
102000004877 Insulin Human genes 0.000 description 3
108090001061 Insulin Proteins 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 3
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 3
101800000989 Oxytocin Proteins 0.000 description 3
102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 3
241001290151 Prunus avium subsp. avium Species 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
230000036506 anxiety Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
235000019658 bitter taste Nutrition 0.000 description 3
229960004205 carbidopa Drugs 0.000 description 3
TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
239000013043 chemical agent Substances 0.000 description 3
235000019693 cherries Nutrition 0.000 description 3
VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 3
229960004022 clotrimazole Drugs 0.000 description 3
238000000354 decomposition reaction Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000001647 drug administration Methods 0.000 description 3
238000012377 drug delivery Methods 0.000 description 3
230000002526 effect on cardiovascular system Effects 0.000 description 3
239000003292 glue Substances 0.000 description 3
230000006872 improvement Effects 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
239000008101 lactose Substances 0.000 description 3
229960001474 meclozine Drugs 0.000 description 3
230000004060 metabolic process Effects 0.000 description 3
238000000465 moulding Methods 0.000 description 3
RLANKEDHRWMNRO-UHFFFAOYSA-M oxtriphylline Chemical compound C[N+](C)(C)CCO.O=C1N(C)C(=O)N(C)C2=C1[N-]C=N2 RLANKEDHRWMNRO-UHFFFAOYSA-M 0.000 description 3
229940100256 oxtriphylline Drugs 0.000 description 3
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 3
229960001723 oxytocin Drugs 0.000 description 3
230000004044 response Effects 0.000 description 3
210000003296 saliva Anatomy 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000001629 suppression Effects 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
206010020772 Hypertension Diseases 0.000 description 2
208000019695 Migraine disease Diseases 0.000 description 2
208000018737 Parkinson disease Diseases 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
206010047700 Vomiting Diseases 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
230000036592 analgesia Effects 0.000 description 2
229940121375 antifungal agent Drugs 0.000 description 2
239000003429 antifungal agent Substances 0.000 description 2
230000003139 buffering effect Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
230000001427 coherent effect Effects 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
229960004281 desmopressin Drugs 0.000 description 2
NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
230000000857 drug effect Effects 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
239000012467 final product Substances 0.000 description 2
235000021474 generally recognized As safe (food) Nutrition 0.000 description 2
235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 2
239000003168 generic drug Substances 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000000366 juvenile effect Effects 0.000 description 2
206010027599 migraine Diseases 0.000 description 2
229940126701 oral medication Drugs 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
230000008447 perception Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000006187 pill Substances 0.000 description 2
238000009101 premedication Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 2
230000009467 reduction Effects 0.000 description 2
210000005227 renal system Anatomy 0.000 description 2
230000028327 secretion Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
238000010186 staining Methods 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
229940126585 therapeutic drug Drugs 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
BFCDFTHTSVTWOG-YLJYHZDGSA-N (1S,2R)-2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol Chemical compound CCCCCCCCN[C@H](C)[C@@H](O)C1=CC=C(SC(C)C)C=C1 BFCDFTHTSVTWOG-YLJYHZDGSA-N 0.000 description 1
BJFIDCADFRDPIO-DZCXQCEKSA-N (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-(phenylmethyl)-1,2-dithia-5,8,11,14,17-pentazacycloeicos-4-yl]-oxomethyl]-2-pyrrolidinecarboxamide Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1 BJFIDCADFRDPIO-DZCXQCEKSA-N 0.000 description 1
KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 1
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
JJBCTCGUOQYZHK-UHFFFAOYSA-N 2-acetyloxybenzoate;(5-amino-1-carboxypentyl)azanium Chemical compound OC(=O)C(N)CCCC[NH3+].CC(=O)OC1=CC=CC=C1C([O-])=O JJBCTCGUOQYZHK-UHFFFAOYSA-N 0.000 description 1
FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 description 1
-1 25 "compritor 888 Substances 0.000 description 1
MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
244000291564 Allium cepa Species 0.000 description 1
235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
244000003416 Asparagus officinalis Species 0.000 description 1
235000005340 Asparagus officinalis Nutrition 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
206010063659 Aversion Diseases 0.000 description 1
235000013162 Cocos nucifera Nutrition 0.000 description 1
244000060011 Cocos nucifera Species 0.000 description 1
208000032170 Congenital Abnormalities Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
208000006558 Dental Calculus Diseases 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
WVVSZNPYNCNODU-CJBNDPTMSA-N Ergometrine Natural products C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-CJBNDPTMSA-N 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
241000233866 Fungi Species 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
108010048179 Lypressin Proteins 0.000 description 1
WVVSZNPYNCNODU-XTQGRXLLSA-N Lysergic acid propanolamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-XTQGRXLLSA-N 0.000 description 1
235000014749 Mentha crispa Nutrition 0.000 description 1
244000024873 Mentha crispa Species 0.000 description 1
206010030216 Oesophagitis Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000004880 Polyuria Diseases 0.000 description 1
208000018525 Postpartum Hemorrhage Diseases 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
206010038687 Respiratory distress Diseases 0.000 description 1
244000299461 Theobroma cacao Species 0.000 description 1
LYZGJWXNOGIVQA-UHFFFAOYSA-M Thiamylal sodium Chemical compound [Na+].CCCC(C)C1(CC=C)C(=O)NC([S-])=NC1=O LYZGJWXNOGIVQA-UHFFFAOYSA-M 0.000 description 1
235000009754 Vitis X bourquina Nutrition 0.000 description 1
235000012333 Vitis X labruscana Nutrition 0.000 description 1
240000006365 Vitis vinifera Species 0.000 description 1
235000014787 Vitis vinifera Nutrition 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
JSZILQVIPPROJI-CEXWTWQISA-N [(2R,3R,11bS)-3-(diethylcarbamoyl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] acetate Chemical compound C1CC2=CC(OC)=C(OC)C=C2[C@H]2N1C[C@@H](C(=O)N(CC)CC)[C@H](OC(C)=O)C2 JSZILQVIPPROJI-CEXWTWQISA-N 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
229960003556 aminophylline Drugs 0.000 description 1
FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
238000001949 anaesthesia Methods 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
229940035674 anesthetics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
239000004004 anti-anginal agent Substances 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
230000002686 anti-diuretic effect Effects 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
229940035678 anti-parkinson drug Drugs 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
229940124538 antidiuretic agent Drugs 0.000 description 1
229940125683 antiemetic agent Drugs 0.000 description 1
239000002111 antiemetic agent Substances 0.000 description 1
230000009118 appropriate response Effects 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
229940092705 beclomethasone Drugs 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
150000001557 benzodiazepines Chemical class 0.000 description 1
229960004564 benzquinamide Drugs 0.000 description 1
235000021028 berry Nutrition 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000007698 birth defect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
210000005178 buccal mucosa Anatomy 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
235000013736 caramel Nutrition 0.000 description 1
238000013131 cardiovascular procedure Methods 0.000 description 1
238000005266 casting Methods 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
235000013339 cereals Nutrition 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
235000019219 chocolate Nutrition 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000005056 compaction Methods 0.000 description 1
239000002131 composite material Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
230000001934 delay Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
229960002845 desmopressin acetate Drugs 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
229940072271 diprivan Drugs 0.000 description 1
229960002819 diprophylline Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
229960000394 droperidol Drugs 0.000 description 1
RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
239000000975 dye Substances 0.000 description 1
KSCFJBIXMNOVSH-UHFFFAOYSA-N dyphylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)CO)C=N2 KSCFJBIXMNOVSH-UHFFFAOYSA-N 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
229960001405 ergometrine Drugs 0.000 description 1
AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 1
229960003745 esmolol Drugs 0.000 description 1
208000006881 esophagitis Diseases 0.000 description 1
IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000010304 firing Methods 0.000 description 1
238000010579 first pass effect Methods 0.000 description 1
239000011888 foil Substances 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
230000035876 healing Effects 0.000 description 1
UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
239000005414 inactive ingredient Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000007689 inspection Methods 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
239000011872 intimate mixture Substances 0.000 description 1
229940039009 isoproterenol Drugs 0.000 description 1
230000007803 itching Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
239000010985 leather Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
125000003473 lipid group Chemical group 0.000 description 1
235000020094 liqueur Nutrition 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
230000008949 local secretion Effects 0.000 description 1
230000004807 localization Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229960003837 lypressin Drugs 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
238000005399 mechanical ventilation Methods 0.000 description 1
229940041616 menthol Drugs 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
229960001620 methohexital sodium Drugs 0.000 description 1
KDXZREBVGAGZHS-UHFFFAOYSA-M methohexital sodium Chemical compound [Na+].CCC#CC(C)C1(CC=C)C(=O)N=C([O-])N(C)C1=O KDXZREBVGAGZHS-UHFFFAOYSA-M 0.000 description 1
229960001186 methysergide Drugs 0.000 description 1
229960004503 metoclopramide Drugs 0.000 description 1
TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
229960003793 midazolam Drugs 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
235000013923 monosodium glutamate Nutrition 0.000 description 1
239000004223 monosodium glutamate Substances 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
229960000988 nystatin Drugs 0.000 description 1
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
229960002657 orciprenaline Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
VCCZBYPHZRWKFY-XIKOKIGWSA-N oxazolam Chemical compound C1([C@]23C4=CC(Cl)=CC=C4NC(=O)CN2C[C@H](O3)C)=CC=CC=C1 VCCZBYPHZRWKFY-XIKOKIGWSA-N 0.000 description 1
229950006124 oxazolam Drugs 0.000 description 1
239000002863 oxytocic agent Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
238000000053 physical method Methods 0.000 description 1
239000011148 porous material Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
229960003111 prochlorperazine Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
229960004291 sucralfate Drugs 0.000 description 1
229960003967 suloctidil Drugs 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229960000195 terbutaline Drugs 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
229960002178 thiamazole Drugs 0.000 description 1
229960001525 thiamylal sodium Drugs 0.000 description 1
238000004448 titration Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
FEZBIKUBAYAZIU-UHFFFAOYSA-N trimethobenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NCC=2C=CC(OCCN(C)C)=CC=2)=C1 FEZBIKUBAYAZIU-UHFFFAOYSA-N 0.000 description 1
229960004161 trimethobenzamide Drugs 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
229940072690 valium Drugs 0.000 description 1
238000004078 waterproofing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/368—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/801—Pediatric

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Nutrition Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Polymers & Plastics (AREA)
Physiology (AREA)
Microbiology (AREA)
Inorganic Chemistry (AREA)
Food Science & Technology (AREA)
Zoology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Basic Packing Technique (AREA)
Materials For Medical Uses (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK199200193A 1985-05-01 1992-02-14 Komprimerede pulverlægemidler DK175779B1 (da)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US72930185		1985-05-01
US06/729,301 US4671953A (en)	1985-05-01	1985-05-01	Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
US8903518		1989-08-16
PCT/US1989/003518 WO1991003099A1 (fr)	1985-05-01	1989-08-16	Medicaments a base de poudre comprimee
CA609378		1989-08-24
CA000609378A CA1339190C (fr)	1989-08-24	1989-08-24	Compositions et methodes de fabrication de medicaments dans des poudres comprimees

Publications (3)

Publication Number	Publication Date
DK19392A DK19392A (da)	1992-02-14
DK19392D0 DK19392D0 (da)	1992-02-14
DK175779B1 true DK175779B1 (da)	2005-02-14

Family

ID=25672976

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK199200193A DK175779B1 (da)	1985-05-01	1992-02-14	Komprimerede pulverlægemidler
DK030192A DK30192A (da)	1985-05-01	1992-03-05	Laegemiddelholdig matrix

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK030192A DK30192A (da)	1985-05-01	1992-03-05	Laegemiddelholdig matrix

Country Status (9)

Country	Link
US (1)	US4671953A (fr)
EP (4)	EP0404205B1 (fr)
JP (1)	JP2704019B2 (fr)
AT (1)	ATE116131T1 (fr)
AU (1)	AU641622B2 (fr)
CA (2)	CA1271421A (fr)
DE (2)	DE3650189T2 (fr)
DK (2)	DK175779B1 (fr)
WO (2)	WO1991003099A1 (fr)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4863737A (en) *	1985-05-01	1989-09-05	University Of Utah	Compositions and methods of manufacture of compressed powder medicaments
US5855908A (en) *	1984-05-01	1999-01-05	University Of Utah Research Foundation	Non-dissolvable drug-containing dosage-forms for use in the transmucosal delivery of a drug to a patient
US4885173A (en) *	1985-05-01	1989-12-05	University Of Utah	Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities
US4671953A (en) *	1985-05-01	1987-06-09	University Of Utah Research Foundation	Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
US5132114A (en) *	1985-05-01	1992-07-21	University Of Utah Research Foundation	Compositions and methods of manufacture of compressed powder medicaments
US5288497A (en) *	1985-05-01	1994-02-22	The University Of Utah	Compositions of oral dissolvable medicaments
US5122127A (en) *	1985-05-01	1992-06-16	University Of Utah	Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
US5783207A (en) *	1985-05-01	1998-07-21	University Of Utah Research Foundation	Selectively removable nicotine-containing dosage form for use in the transmucosal delivery of nicotine
US5176151A (en) *	1987-08-27	1993-01-05	Harding Glen R	Oral prophylactics
US5066502A (en) *	1988-12-05	1991-11-19	Eales George E	Confection and safety support handle
US5139023A (en) *	1989-06-02	1992-08-18	Theratech Inc.	Apparatus and method for noninvasive blood glucose monitoring
AU684888B2 (en) *	1989-09-05	1998-01-08	University Of Utah Research Foundation	Method and compositions for noninvasive dose to effect administration of lipophilic drugs
US5824334A (en) *	1989-09-05	1998-10-20	University Of Utah Research Foundation	Tobacco substitute
WO1991003233A1 (fr) *	1989-09-05	1991-03-21	University Of Utah Research Foundation	Methode de preparation permettant l'administration non invasive de medicaments lipophiles doses en fonction de l'effet recherche
USH1228H (en)	1990-10-04	1993-09-07		Medicated lollipop
US5296234A (en) *	1991-10-11	1994-03-22	Abbott Laboratories	Holder and packaging for a hardened medicated matrix
DK0615438T3 (da) *	1991-12-05	1996-11-11	Mallinckrodt Veterinary Inc	En carbohydratglasmatrix til langvarig frigivelse af et terapeutisk middel
HU9203780D0 (en) *	1991-12-12	1993-03-29	Sandoz Ag	Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
NL9200397A (nl) *	1992-03-04	1993-10-01	Philips Nv	Informatie-optekeninrichting.
US5302394A (en) *	1992-07-14	1994-04-12	Mcneil-Ppc, Inc.	Dextromethorphan continuous lozenge manufacturing process
WO1994025011A1 (fr) *	1993-04-29	1994-11-10	Mildred Blankenship	Systeme d'apport medicamenteux
WO1995003771A1 (fr) *	1993-08-03	1995-02-09	Pacific Rim Productions Pty. Ltd.	Traitement de troubles buccaux
US5419911A (en) *	1993-09-28	1995-05-30	Abbott Laboratories	Holder and overcap assembly for a medicated matrix
US5679714A (en) *	1995-06-07	1997-10-21	Weg; Stuart L.	Administration of ketamine for detoxification and treatment of tobacco addiction
US5543434A (en) *	1994-02-25	1996-08-06	Weg; Stuart L.	Nasal administration of ketamine to manage pain
US6165495A (en) *	1994-04-29	2000-12-26	Blankenship; Mildred	Drug delivery system
WO1996000072A1 (fr) *	1994-06-23	1996-01-04	The Procter & Gamble Company	Traitement du besoin de nicotine et/ou des symptomes de manque du fumeur au moyen d'une composition contenant de la nicotine et de la cafeine ou de la xanthine, pouvant etre administree par voie transdermique ou a travers les muqueuses
CA2230690C (fr) *	1995-08-30	2008-12-23	Stuart L. Weg	Administration de ketamine pour gerer la douleur et reduire la dependance aux medicaments
US6248789B1 (en) *	1996-08-29	2001-06-19	Stuart L. Weg	Administration of ketamine to manage pain and to reduce drug dependency
US6767925B1 (en) *	1996-10-31	2004-07-27	Joseph A. Deihl	Sprayable analgesic composition and method of use
GB9717770D0 (en) *	1997-08-21	1997-10-29	Scherer Ltd R P	Pharmaceutical composition
US20030091629A1 (en) *	1998-03-27	2003-05-15	Cima Labs Inc.	Sublingual buccal effervescent
US6974590B2 (en) *	1998-03-27	2005-12-13	Cima Labs Inc.	Sublingual buccal effervescent
US20030118645A1 (en) *	1998-04-29	2003-06-26	Pather S. Indiran	Pharmaceutical compositions for rectal and vaginal administration
US6103257A (en) *	1998-07-17	2000-08-15	Num-Pop, Inc.	System for delivering pharmaceuticals to the buccal mucosa
US6344222B1 (en)	1998-09-03	2002-02-05	Jsr Llc	Medicated chewing gum delivery system for nicotine
US6358060B2 (en) *	1998-09-03	2002-03-19	Jsr Llc	Two-stage transmucosal medicine delivery system for symptom relief
US6387381B2 (en) *	1998-09-24	2002-05-14	Ez-Med Company	Semi-moist oral delivery system
US6159492A (en) *	1999-03-04	2000-12-12	Manzone; Cheryl	Drug storage and delivery system containing a medicated lollipop
US6248760B1 (en) *	1999-04-14	2001-06-19	Paul C Wilhelmsen	Tablet giving rapid release of nicotine for transmucosal administration
JP2002542183A (ja) *	1999-04-16	2002-12-10	ノボノルディスクアクティーゼルスカブ	成形可能な乾燥した医薬製剤
CA2374003C (fr) *	1999-05-17	2008-02-12	Aesgen, Inc.	Assimilation cellulaire amelioree d'agents bioactifs
US20040115252A1 (en) *	1999-06-25	2004-06-17	Thomas Leon	Methods of treating illnesses in non-human mammals
US7693697B2 (en)	1999-12-07	2010-04-06	University Of Utah Research Foundation	Anesthesia drug monitor
US6207193B1 (en) *	1999-12-27	2001-03-27	Stephen E. Feldman	Transdermal drug delivery system
US8642051B2 (en) *	2000-03-21	2014-02-04	Suzanne Jaffe Stillman	Method of hydration; infusion packet system(s), support member(s), delivery system(s), and method(s); with business model(s) and Method(s)
WO2001089476A1 (fr) *	2000-05-19	2001-11-29	Npd Llc	Gommes a macher, pastilles, bonbons, tablettes, liquides et sprays destines a une administration efficace de medicaments et de supplements dietetiques
ATE355813T1 (de) *	2000-07-14	2007-03-15	Novo Nordisk As	Verfahren zum formen einer pharmazeutischen zusammensetzung in einem verpackungsmaterial
US20020106407A1 (en) *	2000-12-11	2002-08-08	Dennis Coleman	Method and apparatus for treating breakthrough pain
JP4850346B2 (ja) *	2001-03-15	2012-01-11	救急薬品工業株式会社	粘膜貼付剤
US6559180B2 (en)	2001-03-27	2003-05-06	Yuri Busiashvili	Nitroglycerin-menthol potentiation for treatment of angina
US7243799B2 (en) *	2001-05-15	2007-07-17	Cephalon, Inc.	Portable container for disposing of a medicated oral dosage form
EP1423116A1 (fr) *	2001-08-14	2004-06-02	Biotie Therapies Corp.	Traitement de l'alcoolisme ou de l'abus d'alcool
US6932978B2 (en) *	2001-10-18	2005-08-23	James Benjamin Huntley	Double-headed, closed-mouth cough suppressant and cold relief device
US20030130314A1 (en) *	2001-12-17	2003-07-10	Pascal Druzgala	Analgesic delivery systems and methods of use
US8454997B2 (en)	2001-12-18	2013-06-04	Novo Nordisk A/S	Solid dose micro implant
GB0217056D0 (en) *	2002-07-23	2002-08-28	Ass Octel	Use
CA2493764C (fr) *	2002-08-01	2011-05-24	Aesgen, Inc.	Traitement ameliore du cancer avec la glutamine
JP2006510618A (ja)	2002-11-18	2006-03-30	ヤウポンセラピューティクス，インコーポレーテッド	ノルケタミンおよびケタミン／ノルケタミンプロドラッグの鎮痛的使用
US20040115244A1 (en) *	2002-12-17	2004-06-17	Holgate Eric Jamison	Methods and compositions for nicotine replacement therapy
US20080213363A1 (en) *	2003-01-23	2008-09-04	Singh Nikhilesh N	Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
US20040253307A1 (en) *	2003-02-04	2004-12-16	Brian Hague	Sugar-free oral transmucosal solid dosage forms and uses thereof
US20040265359A1 (en) *	2003-04-17	2004-12-30	Sacks Gordon S.	Oral delivery formulations of L-glutamine
US20040213828A1 (en) *	2003-04-23	2004-10-28	Smith David J.	Pain relief lollipop compositions and methods
JP5137286B2 (ja) *	2003-06-10	2013-02-06	帝國製薬株式会社	フェンタニル含有口腔粘膜貼付剤
US20070059346A1 (en) *	2003-07-01	2007-03-15	Todd Maibach	Film comprising therapeutic agents
US20050065175A1 (en) *	2003-09-24	2005-03-24	Xanodyne Pharmacal, Inc.	Oral transmucosal methadone
US20080317828A1 (en) *	2003-09-24	2008-12-25	Kazuyoshi Furusawa	Fentanyl compound-containing edible patch to be applied to oral mucosa
US8157788B2 (en)	2003-11-06	2012-04-17	Paolo L. Manfredi	Multi-site drug delivery platform
CN102078310B (zh) *	2003-12-31	2013-01-23	奇马实验室公司	大体线性的泡腾口服芬太尼剂型和施用方法
US7862833B2 (en) *	2003-12-31	2011-01-04	Cima Labs, Inc.	Effervescent oral opiate dosage forms and methods of administering opiates
WO2005065317A2 (fr) *	2003-12-31	2005-07-21	Cima Labs Inc.	Forme posologique orale effervescente a base de fentanyl et procedes permettant d'administrer du fentanyl
US20060002989A1 (en) *	2004-06-10	2006-01-05	Ahmed Salah U	Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
US20060004035A1 (en) *	2004-06-25	2006-01-05	Cephalon, Inc.	System for identification of a pharmaceutical product
WO2006012536A2 (fr)	2004-07-22	2006-02-02	Ritter Andrew J	Procedes et compositions pour le traitement de l'intolerance au lactose
US7318920B2 (en) *	2004-09-27	2008-01-15	Ez-Med Company	Low water activity nutritional product having beneficial microbial and high oil content
EP1845979A4 (fr)	2005-01-19	2009-11-11	Neurohealing Pharmaceuticals I	Methodes et compositions permettant de reduire la production de salive
FR2883179B1 (fr) *	2005-03-18	2009-04-17	Ethypharm Sa	Comprime enrobe
CA2610454C (fr) *	2005-06-03	2014-02-11	Duramed Pharmaceuticals, Inc.	Fixation d'une poignee sur une forme galenique orale solide
US7908729B2 (en) *	2005-06-03	2011-03-22	Teva Women's Health, Inc.	Method for making a lollipop
US20070104763A1 (en) *	2005-11-10	2007-05-10	Navinta Llc	Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making
GB0523031D0 (en) *	2005-11-11	2005-12-21	Yaupon Therapeutics	Enhancement of morphine analgesia by s(-)-norketamine
US9289583B2 (en) *	2006-01-06	2016-03-22	Acelrx Pharmaceuticals, Inc.	Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8357114B2 (en)	2006-01-06	2013-01-22	Acelrx Pharmaceuticals, Inc.	Drug dispensing device with flexible push rod
US8535714B2 (en)	2006-01-06	2013-09-17	Acelrx Pharmaceuticals, Inc.	Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252328B2 (en) *	2006-01-06	2012-08-28	Acelrx Pharmaceuticals, Inc.	Bioadhesive drug formulations for oral transmucosal delivery
US8252329B2 (en)	2007-01-05	2012-08-28	Acelrx Pharmaceuticals, Inc.	Bioadhesive drug formulations for oral transmucosal delivery
US8865743B2 (en)	2006-01-06	2014-10-21	Acelrx Pharmaceuticals, Inc.	Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9066847B2 (en) *	2007-01-05	2015-06-30	Aceirx Pharmaceuticals, Inc.	Storage and dispensing devices for administration of oral transmucosal dosage forms
CN106727271B (zh) *	2006-01-06	2020-02-14	阿塞尔Rx制药有限公司	小体积口腔经粘膜剂型
US8753308B2 (en)	2006-01-06	2014-06-17	Acelrx Pharmaceuticals, Inc.	Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8202535B2 (en)	2006-01-06	2012-06-19	Acelrx Pharmaceuticals, Inc.	Small-volume oral transmucosal dosage forms
EP1983827A4 (fr)	2006-02-01	2013-07-10	Stuart L Weg	Utilisation de compositions antifongiques pour traiter des conditions gastro-intestinales superieures
US20070218171A1 (en) *	2006-03-20	2007-09-20	Mehrle Hannah E	Frozen pet novelties
US20070260491A1 (en) *	2006-05-08	2007-11-08	Pamela Palmer	System for delivery and monitoring of administration of controlled substances
US20070299687A1 (en) *	2006-06-23	2007-12-27	Pamela Palmer	Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed
AR058431A1 (es) *	2006-07-12	2008-02-06	Karen Elizabeth Quiroga	Procedimiento para la fabricacion de analgesicos a base de fentanilo para su administracion por via oral transmucosa bajo forma de caramelo
US8642016B2 (en) *	2006-07-21	2014-02-04	Jsrnti, Llc	Medicinal delivery system, and related methods
SI2124556T1 (sl)	2006-10-09	2015-01-30	Charleston Laboratories, Inc.	Farmacevtske sestave
US20100215774A1 (en) *	2007-02-09	2010-08-26	Todd Maibach	Film comprising nitroglycerin
CA2677281C (fr) *	2007-02-09	2019-10-29	Durect Corporation	Formes posologiques par voie orale comprenant du sufentanile et de la naloxone
US20080287494A1 (en) *	2007-04-24	2008-11-20	Cephalon, Inc.	Transmucosal treatment methods in patients with mucositis
US20090004254A1 (en) *	2007-06-19	2009-01-01	Todd Maibach	Film comprising active drugs
US20110223248A1 (en) *	2007-12-12	2011-09-15	Ritter Pharmaceuticals, Inc.	Methods and compositions for treating lactose intolerance
EP3090743A1 (fr)	2008-01-09	2016-11-09	Charleston Laboratories, Inc.	Compositions pharmaceutiques
US20090191257A1 (en) *	2008-01-29	2009-07-30	Innovative Pharmaceuticals, Llc	Pain relief lollipop compositions and methods
US20100055050A1 (en) *	2008-08-30	2010-03-04	Kathleen Moore	Nicotine chewing gum on a stick
US8945592B2 (en)	2008-11-21	2015-02-03	Acelrx Pharmaceuticals, Inc.	Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
WO2010090876A2 (fr)	2009-01-21	2010-08-12	University Of Florida Research Foundation, Inc.	Administration d'un peptide de la satiété
EP2400839B1 (fr)	2009-02-24	2016-09-07	Ritter Pharmaceuticals, Inc.	Formulations prébiotiques et méthodes d'utilisation
CA2767576C (fr)	2009-07-08	2020-03-10	Charleston Laboratories Inc.	Compositions pharmaceutiques refermant un antiemetique et un analgesiqueopioide
WO2011064316A2 (fr)	2009-11-25	2011-06-03	Paolo Botti	Administration de peptides par voie muqueuse
EP3202406A1 (fr)	2010-04-28	2017-08-09	Ritter Pharmaceuticals, Inc.	Formulations prébiotiques et méthodes d'utilisation
EP2526971A1 (fr)	2011-05-25	2012-11-28	ArisGen SA	Administration de médicaments par les muqueuses
PL2668947T3 (pl) *	2012-05-31	2017-06-30	G. Pohl-Boskamp Gmbh & Co. Kg	Indukcja arteriogenezy donorem NO, takim jak nitrogliceryna
EP3125905A4 (fr)	2014-04-04	2017-11-08	Ritter Pharmaceuticals, Inc.	Méthodes et compositions pour la modification du microbiome
US9392814B2 (en)	2014-06-06	2016-07-19	Nicholas J. Singer	Delivery system for drinks
NZ732808A (en)	2014-12-23	2021-12-24	Acelrx Pharmaceuticals Inc	Systems, devices and methods for dispensing oral transmucosal dosage forms
US9918993B2 (en) *	2015-06-19	2018-03-20	Imprimis Pharmaceuticals, Inc.	Pharmaceutical compositions for anesthesiological applications
US20200297734A1 (en)	2015-06-19	2020-09-24	Melt Pharmaceuticals, Inc.	Pharmaceutical compositions and methods for anesthesiological applications
US10391102B2 (en)	2015-06-19	2019-08-27	Melt Pharmaceuticals, Inc.	Pharmaceutical compositions and methods for anesthesiological applications
US10555952B2 (en)	2015-06-19	2020-02-11	Melt Pharmaceuticals, Inc.	Pharmaceutical compositions and methods for anesthesiological applications
USD773313S1 (en)	2015-06-23	2016-12-06	Nicholas J. Singer	Package
CA3055170A1 (fr)	2016-03-04	2017-09-08	Charleston Laboratories, Inc.	Compositions pharmaceutiques
US11311633B2 (en)	2016-04-16	2022-04-26	University Of Florida Research Foundation, Incorporated	Satiation peptides for weight loss and altered taste sensitivity
WO2019118984A2 (fr)	2017-12-15	2019-06-20	Solarea Bio, Inc.	Compositions microbiennes et méthodes de traitement du diabète de type 2, de l'obésité et du syndrome métabolique
US11980647B2 (en)	2018-09-05	2024-05-14	Solarea Bio, Inc.	Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
CA3111795A1 (fr)	2018-09-05	2020-03-12	Solarea Bio, Inc.	Methodes et compositions pour le traitement de maladie musculo-squelettiques
EP3986163A2 (fr)	2019-06-19	2022-04-27	Solarea Bio, Inc.	Compositions microbiennes et procédés de production d'assemblages probiotiques améliorés
IT202100004880A1 (it) *	2021-03-02	2022-09-02	Altergon Sa	Composizione farmaceutica solida orodispersibile in film contenente lorazepam
CA3238788A1 (fr)	2021-11-22	2023-05-25	Eric Michael Schott	Methodes et compositions pour le traitement de maladies musculo-squelettiques, le traitement d'une inflammation et la prise en charge de symptomes de la menopause
US20230190834A1 (en)	2021-12-21	2023-06-22	Solarea Bio, Inc.	Immunomodulatory compositions comprising microbial entities

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US109677A (en) *		1870-11-29		Improvement in confectionery for druggists
US1430642A (en) *	1921-01-29	1922-10-03	Phillip E Gross	Artificial fishing bait
US1593858A (en) *	1923-02-12	1926-07-27	Robert W Venable	Confection
US1971560A (en) *	1928-10-22	1934-08-28	Parker Meyer Dennis Company	Candy and holder therefor
US1847415A (en) *	1929-12-31	1932-03-01	Silver S Snell	Holder for candy suckers
US1915614A (en) *	1930-12-22	1933-06-27	Parker Charles	Solidified edible and method of making same
US2096611A (en) *	1935-02-07	1937-10-19	Parker Meyer Dennis Company	Confection
US2208120A (en) *	1938-03-02	1940-07-16	William B Coleman	Pharmaceutical preparation and method of making same
US2246778A (en) *	1939-12-21	1941-06-24	Edward E Cahoon	Safety handle for confections
US2295042A (en) *	1941-08-25	1942-09-08	Robert L Llewellyn	Fish plug
GB550296A (en) *	1941-11-17	1943-01-01	British Oxygen Co Ltd	Improvements in or relating to the administration of inhalant gas mixtures
US2323656A (en) *	1942-07-28	1943-07-06	Helfenstein John	Fishhook
US2508560A (en) *	1946-10-22	1950-05-23	Mozel A Adams	Fishing lure
GB628709A (en) *	1947-10-06	1949-09-02	William Edmondson	An appliance for the production and administration of gas-vapour mixtures
US2488272A (en) *	1948-08-06	1949-11-15	Harry E Davis	Cellophane stick and method of making it
US2469589A (en) *	1948-09-20	1949-05-10	Toy Pop Corp	Confection with support therefor
GB646680A (en) *	1948-10-27	1950-11-29	William Edmondson	Apparatus for mixing the vapour of a volatile anaesthetic with air
US2915061A (en) *	1956-12-24	1959-12-01	Cyprane Ltd	Volatile anaesthetic vaporising apparatus
US2926121A (en) *	1957-03-20	1960-02-23	American Home Prod	Therapeutic candy-like product and its preparation
US2857908A (en) *	1957-04-26	1958-10-28	Leslie S Cornfield	Candy coated tongue depressor
US2897624A (en) *	1958-06-27	1959-08-04	Frederick O Yakel	Conservation fishhooks
US2963404A (en) *	1958-09-05	1960-12-06	Pfizer & Co C	Tannate candy making, and product
GB968054A (en) *	1962-02-15	1964-08-26	Cyprane Ltd	Improvements in volatile anaesthetic vaporising apparatus
US3264115A (en) *	1962-07-10	1966-08-02	Harry E Davis	Safety lollipop
US3271256A (en) *	1963-03-21	1966-09-06	Richardson Merrell Inc	Chloroform in hard candy
US3172179A (en) *	1963-08-12	1965-03-09	John V Schafer	Collar fastener
GB1071659A (en) *	1964-06-09	1967-06-07	Cyprane Ltd	Improvements in or relating to volatile anaesthetic vaporising apparatus
US3341414A (en) *	1964-08-27	1967-09-12	Merck & Co Inc	N-cyclohexylsulfamate solubilized medication
US3418743A (en) *	1967-05-02	1968-12-31	Roy H. Halvorsen	Fish lure with retractable hooks
US3797494A (en) *	1969-04-01	1974-03-19	Alza Corp	Bandage for the administration of drug by controlled metering through microporous materials
US3556811A (en) *	1969-08-11	1971-01-19	Walton J Smith	Low-fermentability hard candy
US3996934A (en) *	1971-08-09	1976-12-14	Alza Corporation	Medical bandage
FI50578C (fi) *	1972-09-05	1976-05-10	Haemeen Anttila Yrjoe Sakari	Syöksykoukuilla varustettu uistin
US3867927A (en) *	1974-06-13	1975-02-25	Patrick F Hergott	Tongue blade sucker
JPS5138412A (en) *	1974-09-24	1976-03-31	Nippon Kayaku Kk	Kokoseizai no seiho
US3943928A (en) *	1974-09-25	1976-03-16	Lariccia Anthony H	Eliminating the safety hazard in oral dissolution of a solid
US4093709A (en) *	1975-01-28	1978-06-06	Alza Corporation	Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4131648A (en) *	1975-01-28	1978-12-26	Alza Corporation	Structured orthoester and orthocarbonate drug delivery devices
US4060084A (en) *	1976-09-07	1977-11-29	Alza Corporation	Method and therapeutic system for providing chemotherapy transdermally
US4139627A (en) *	1977-10-06	1979-02-13	Beecham Inc.	Anesthetic lozenges
EP0001907B1 (fr) *	1977-11-07	1981-02-11	Beecham Inc.	Pastilles à sucer anesthésiques et procédé pour leur préparation
US4291015A (en) *	1979-08-14	1981-09-22	Key Pharmaceuticals, Inc.	Polymeric diffusion matrix containing a vasodilator
JPS5843368B2 (ja) *	1980-10-30	1983-09-27	日東電工株式会社	消炎鎮痛貼付剤
US4346709A (en) *	1980-11-10	1982-08-31	Alza Corporation	Drug delivery devices comprising erodible polymer and erosion rate modifier
IL61721A (en) *	1980-12-16	1984-03-30	Blank Izhak	Nitroglycerin preparations
JPS6059207B2 (ja) *	1981-03-13	1985-12-24	日東電工株式会社	複合製剤の製法
AU8533582A (en) *	1981-07-10	1984-01-12	Reckitt & Colman Products Limited	Stable solutions of buprenorphine
US4372942A (en) *	1981-08-13	1983-02-08	Beecham Inc.	Candy base and liquid center hard candy made therefrom
CA1208558A (fr) *	1982-10-07	1986-07-29	Kazuo Kigasawa	Medicament oral
US4749575A (en) *	1983-10-03	1988-06-07	Bio-Dar Ltd.	Microencapsulated medicament in sweet matrix
US4551329A (en) *	1984-01-20	1985-11-05	Joan Harris	Oral medicament lollipop
US4588580B2 (en) *	1984-07-23	1999-02-16	Alaz Corp	Transdermal administration of fentanyl and device therefor
US4671953A (en) *	1985-05-01	1987-06-09	University Of Utah Research Foundation	Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
US4695463A (en) *	1985-05-24	1987-09-22	Warner-Lambert Company	Delivery system for active ingredients and preparation thereof
US4755386A (en) *	1986-01-22	1988-07-05	Schering Corporation	Buccal formulation
US4764378A (en) *	1986-02-10	1988-08-16	Zetachron, Inc.	Buccal drug dosage form
FR2611501B1 (fr) *	1987-03-04	1991-12-06	Corbiere Jerome	Nouvelles compositions pharmaceutiques pour la voie buccale a base d'acetylsalielylate de lysine et leur procede d'obtention

1985
- 1985-05-01 US US06/729,301 patent/US4671953A/en not_active Expired - Lifetime
1986
- 1986-04-25 EP EP90114597A patent/EP0404205B1/fr not_active Expired - Lifetime
- 1986-04-25 DE DE3650189T patent/DE3650189T2/de not_active Expired - Lifetime
- 1986-04-25 AT AT90114597T patent/ATE116131T1/de not_active IP Right Cessation
- 1986-04-25 EP EP86303128A patent/EP0200490B1/fr not_active Expired - Lifetime
- 1986-04-28 CA CA000507763A patent/CA1271421A/fr not_active Expired - Lifetime
1989
- 1989-08-16 WO PCT/US1989/003518 patent/WO1991003099A1/fr not_active Ceased
- 1989-08-16 EP EP89909497A patent/EP0487520B1/fr not_active Expired - Lifetime
- 1989-08-24 CA CA0609378A patent/CA1338978C/fr not_active Expired - Lifetime
- 1989-09-05 JP JP1509843A patent/JP2704019B2/ja not_active Expired - Lifetime
- 1989-09-05 AU AU42063/89A patent/AU641622B2/en not_active Expired
- 1989-09-05 DE DE68926169T patent/DE68926169T2/de not_active Expired - Lifetime
- 1989-09-05 EP EP89910318A patent/EP0490891B1/fr not_active Expired - Lifetime
- 1989-09-05 WO PCT/US1989/003802 patent/WO1991003234A1/fr not_active Ceased
1992
- 1992-02-14 DK DK199200193A patent/DK175779B1/da not_active IP Right Cessation
- 1992-03-05 DK DK030192A patent/DK30192A/da not_active Application Discontinuation

Also Published As

Publication number	Publication date
DE68926169T2 (de)	1996-11-14
EP0490891A4 (en)	1992-09-16
EP0490891A1 (fr)	1992-06-24
EP0487520A4 (en)	1992-08-12
CA1338978C (fr)	1997-03-11
AU641622B2 (en)	1993-09-30
DK30192D0 (da)	1992-03-05
EP0490891B1 (fr)	1996-04-03
AU4206389A (en)	1991-04-08
WO1991003099A1 (fr)	1991-03-07
JPH05500041A (ja)	1993-01-14
CA1271421A (fr)	1990-07-10
DE3650189T2 (de)	1995-05-04
US4671953A (en)	1987-06-09
ATE116131T1 (de)	1995-01-15
JP2704019B2 (ja)	1998-01-26
DK19392A (da)	1992-02-14
DE68926169D1 (de)	1996-05-09
DK19392D0 (da)	1992-02-14
EP0200490B1 (fr)	1991-03-20
DE3650189D1 (de)	1995-02-09
EP0200490A3 (en)	1987-07-01
EP0404205B1 (fr)	1994-12-28
EP0487520B1 (fr)	1995-04-12
EP0404205A1 (fr)	1990-12-27
WO1991003234A1 (fr)	1991-03-21
EP0487520A1 (fr)	1992-06-03
DK30192A (da)	1992-05-05
EP0200490A2 (fr)	1986-11-05

Legal Events

Date	Code	Title	Description
2009-08-31	PUP	Patent expired

Publication	Publication Date	Title
DK175779B1 (da)	2005-02-14	Komprimerede pulverlægemidler
US5132114A (en)	1992-07-21	Compositions and methods of manufacture of compressed powder medicaments
US4863737A (en)	1989-09-05	Compositions and methods of manufacture of compressed powder medicaments
JP2717024B2 (ja)	1998-02-18	口腔溶解性薬剤組成物及びその製造方法
US6602518B2 (en)	2003-08-05	Chewable product including active ingredient
DK2361081T3 (en)	2016-08-15	MULTIPLE INTRAORAL DOSAGE FORM AND USE THEREOF
US20020160043A1 (en)	2002-10-31	Compositions and method of manufacture for oral dissolvable dosage forms
US20110014132A1 (en)	2011-01-20	Solid effervescent mixture for the oral absorption
EP0493380B1 (fr)	1997-10-29	Methode de preparation permettant l'administration non invasive de medicaments lipophiles doses en fonction de l'effet recherche
AU641127B2 (en)	1993-09-16	Compressed powder medicaments
CA1339190C (fr)	1997-07-29	Compositions et methodes de fabrication de medicaments dans des poudres comprimees
KR0129409B1 (ko)	1998-04-09	츄잉 연질정제의 제조방법
Namdev et al.	2022	Unexplored Potential of Medicated Candies And Lozenges as a Drug Delivery System
CA1339075C (fr)	1997-07-29	Methodes et compositions pour l'administration dose-effet non invasive de medicaments lipophiles
AU684888B2 (en)	1998-01-08	Method and compositions for noninvasive dose to effect administration of lipophilic drugs
Allen	2008	Formulation of specialty tablets for slow oral dissolution
JP2000186032A (ja)	2000-07-04	易崩壊性固形物およびその製造方法